Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-04-26 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
第四届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 19th meeting of the 4th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting's attendance, the agenda items discussed, and the voting results. The agenda includes approval of the company's 2023 Q1 report, the 2023 Q1 audit report, a dividend distribution plan, amendments to the company's articles of association, and the proposal to convene an extraordinary general meeting. The document references that the actual reports (Q1 report, audit report, equity distribution plan, and amendments) are disclosed separately on the Beijing Stock Exchange information platform. The document itself does not contain the full financial statements or audit details but is a formal board meeting resolution announcement. Given the content and length (2500 characters), it is not the full quarterly report or audit report but a board meeting resolution announcement. This fits best under Board/Management Information (MANG), which covers announcements of board decisions and management information. Therefore, the classification is MANG with high confidence.
2023-04-26 Chinese
关于召开2023年第六次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2023 sixth extraordinary general meeting of shareholders for Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting date, voting methods, agenda items including the review of the 2023 first quarter audit report and equity distribution plan, and procedural information for shareholders. The document does not contain the actual audit report or financial statements but references that these reports are disclosed elsewhere on the exchange platform. The document is relatively short (3114 characters) and serves as a meeting notice rather than the report itself. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2023-04-26 Chinese
2023年第一季度审计报告
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report for Beijing 康乐卫士生物技术股份有限公司 covering the 3-month period ending March 31, 2023. It includes an audit report by a registered accounting firm (安永华明), with audit opinions, key audit matters, management responsibilities, and detailed financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The presence of a full audit report and comprehensive financial data for a quarterly period indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2023-04-26 Chinese
第四届监事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the approval of several proposals including the 2023 Q1 report, the 2023 Q1 audit report, a dividend distribution plan, and amendments to the company charter related to capital changes. The document references that the actual reports and announcements are disclosed on the Beijing Stock Exchange information platform, indicating this document itself is a meeting resolution announcement rather than the reports themselves. The document length is short (2002 characters) and it does not contain the full financial data or audit details but rather the decisions and voting results on these matters. This fits best with the category of Regulatory Filings (RNS) as it is a formal announcement of supervisory board resolutions and approvals, not the full quarterly report or audit report themselves.
2023-04-26 Chinese
2023年第一季度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding a proposed equity distribution plan (权益分派预案) for the first quarter of 2023 by Beijing Kangle Weishi Biotechnology Co., Ltd. It includes specifics about capital reserves, share capital increase by capital reserve transfer, board and supervisory committee approvals, independent director opinions, and compliance with company articles of association. The document also contains commitments from the company, controlling shareholders, and management regarding profit distribution policies. The document length is 3837 characters, which is relatively short but contains substantive content about the equity distribution plan rather than merely announcing the availability of a report. The content focuses on a planned capital increase by capital reserve transfer (a form of equity distribution) and the related approvals and policies. This fits the category of a Notice of Dividend Amount or equity distribution announcement. Given the nature of the document as a detailed equity distribution plan announcement, the most appropriate classification is Notice of Dividend Amount (DIV).
2023-04-26 Chinese
关于拟变更注册资本及修订《公司章程》公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding a proposed change in registered capital and amendments to the company's articles of association. It details the increase in registered capital and total shares, referencing relevant laws and the need for shareholder approval. The document is relatively short (994 characters) and focuses on corporate governance changes related to capital structure and company bylaws. It is not a full financial report, audit, or earnings release, nor is it a call transcript or AGM materials. It is an official announcement about capital change and related amendments, fitting the category of Share Issue/Capital Change (SHA).
2023-04-26 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.